Pre-treatment hemoglobin levels are important for bladder carcinoma patients with extravesical extension undergoing definitive radiotherapy

Basit Öğe Kaydı
dc.authorscopusid14011859100
dc.authorscopusid56253262800
dc.authorscopusid22979793100
dc.authorscopusid6508269063
dc.contributor.authorYurut-Caloglu V.
dc.contributor.authorCaloglu M.
dc.contributor.authorKaplan M.
dc.contributor.authorInci O.
dc.date.accessioned2024-06-12T10:29:10Z
dc.date.available2024-06-12T10:29:10Z
dc.date.issued2009
dc.description.abstractPurpose: To evaluate prognostic factors affecting local control (LC), distant metastases-free survival (DMFS) and overall survival (OS) in bladder carcinoma patients undergoing extravesical extension. Patients and Methods: We retrospectively reviewed the charts of 61 consecutive patients with T3 or T4 bladder carcinoma, treated with definitive radiotherapy from 1999 through 2007. Results: Median age was 69 years and follow-up was 29 months. The LC rate was 33% at 4 years and was increased in patients with a Hb?12 g/dl (p=0.003) or a LDH<180 U/L (p=0.021) and in those who received concurrent chemotherapy (p=0.022) on univariate analysis. DMFS was affected by anemia (Hb<12 g/dl) (p=0.039), the absence of chemotherapy (p=0.034) and the presence of newlydiagnosed disease (p=0.01). The OS rate was 19% at 4 years. Non-pure transitional cell carcinoma histological type (p=0.024), anemia (p=0.004), elevated LDH (p=0.003), and newly diagnosed disease (p=0.011) were poor prognostic factors on univariate analyses for OS. Anemia was the only negative prognostic factor for LC (p=0.03), DMFS (p=0.002) and OS (p<0.0001) on multivariate analysis. Conclusion: Pre-treatment Hb level is the most important prognostic factor in patients treated with definitive radiotherapy, so that anemia may act as a surrogate biological marker for aggressive disease.en_US
dc.identifier.endpage1158en_US
dc.identifier.issn1513-7368
dc.identifier.issue6en_US
dc.identifier.pmid20192602en_US
dc.identifier.scopus2-s2.0-77956626877en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1151en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17624
dc.identifier.volume10en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnemia; Bladder Cancer; Chemotherapy/Radiotherapy; Prognostic Factor; Turkeyen_US
dc.subjectHemoglobin; Adult; Aged; Article; Bladder Tumor; Blood; Cancer Invasion; Cancer Staging; Chi Square Distribution; Female; Human; Male; Middle Aged; Multimodality Cancer Therapy; Pathology; Prognosis; Proportional Hazards Model; Retrospective Study; Survival; Transitional Cell Carcinoma; Adult; Aged; Aged, 80 And Over; Carcinoma, Transitional Cell; Chi-Square Distribution; Combined Modality Therapy; Female; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasmsen_US
dc.titlePre-treatment hemoglobin levels are important for bladder carcinoma patients with extravesical extension undergoing definitive radiotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu